Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000227573, also called "v-rel reticuloendotheliosis viral oncogene homolog A (avian) pseudogene," is a human pseudogene. It is a non-coding genomic sequence related to the functional RELA gene but does not produce a protein product. Unlike functional RELA (p65), a subunit of the NF-κB transcription factor involved in inflammation and cancer, this pseudogene has no known direct biological or clinical significance as a therapeutic target[7][8]. Key clarification: If you are seeking information on the real molecular drug target, refer to the **RELA** gene or "Transcription factor p65" (NF-κB p65 subunit), which is a well-characterized transcription factor involved in immune response, inflammation, and cancer. The pseudogene should not be confused with this biologically and clinically relevant entity[7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on V-rel reticuloendotheliosis viral oncogene homolog A (avian) pseudogene.